These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35637267)

  • 1. Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study.
    Pessoa JM; da Rosa EL; Américo AD; Motta CL; de Oliveira CZ; Concilio RR; Amigo Filho JU; Marret ACF; Lazar AE; De Gusmão BM; Scheinberg P; Kerbauy FR
    Bone Marrow Transplant; 2022 Aug; 57(8):1313-1318. PubMed ID: 35637267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
    Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
    Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
    Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma.
    Araújo AB; Soares TB; Schmalfuss T; Angeli MH; Furlan JM; Salton GD; Burin MM; Röhsig LM
    Transfusion; 2022 Oct; 62(10):1967-1972. PubMed ID: 36052689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation.
    Makhani SS; Oza SP; Reich-Slotky R; Munshi PN; Biran N; Donato ML; Siegel DS; Vesole DH; Naam S; Rowley SD
    Transplant Cell Ther; 2022 Jun; 28(6):306.e1-306.e7. PubMed ID: 35248777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry.
    Bekadja MA; Boumendil A; Blaise D; Chevallier P; Peggs KS; Salles G; Giebel S; Marks R; Arcese W; Milpied N; Finel H; Gorin NC
    Cytotherapy; 2021 Jun; 23(6):483-487. PubMed ID: 33678598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
    Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
    J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients.
    Noiperm P; Julamanee J; Viboonjuntra P; Lekhakula A
    Ann Transplant; 2023 Jan; 28():e938595. PubMed ID: 36647325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
    Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.
    Akkök CA; Holte MR; Tangen JM; Ostenstad B; Bruserud O
    Transfusion; 2009 Feb; 49(2):354-61. PubMed ID: 18980622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
    Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
    Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study.
    Jennane S; Hasnaoui N; Mahtat EM; Merimi F; Bougar S; El Maaroufi H; Belmekki A; Zafad S; Essakalli M; Mikdame M; Doghmi K
    Transfus Clin Biol; 2020 Aug; 27(3):152-156. PubMed ID: 32334934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.